Additional Relevant Details Our Lenti-D product candidate has the potential to stabilize or prevent progression of CALD with one treatment. Our approach involves inserting a functional copy of the ABCD1 gene in the patient’s hematopoietic stem cells outside the body (ex vivo), then re-introducing the genetically modified cells into the patient.  We are presenting interim data from the Starbeam Study at this year’s American Academy of Neurology (AAN) Annual Meeting.